Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Head and Neck Neoplasms 3Prostatic Neoplasms 2Mouth Neoplasms 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Oligodendroglioma 1Neuroblastoma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 54Temozolomide 50Filgrastim 25Cyclophosphamide 25Etoposide 24Cisplatin 22Carboplatin 22Vincristine 19Chemotherapy, Adjuvant 18Peripheral Blood Stem Cell Transplantation 15Thiotepa 13Carmustine 12Thalidomide 10Methotrexate 9Magnetic Resonance Spectroscopy 9Irinotecan 9Bevacizumab 9Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Lomustine 6X-Rays 5Tamoxifen 5Specimen Handling 5Phantoms, Imaging 5O(6)-benzylguanine 5Ifosfamide 5Erlotinib Hydrochloride 5Drug Therapy 5Celecoxib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Central Nervous System Neoplasms × Fenretinide × Clear all
NCT00006080 2018-06-27

Fenretinide in Treating Patients With Recurrent Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
CNS

Astrocytoma, Brain Neoplasms, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡